💊FDA Approves Lipfendra: First Oral PCSK9 Inhibitor
New drug for high cholesterol just got the green light
TL;DR
The FDA has approved Lipfendra as an oral treatment for hypercholesterolemia. It reduces LDL-C by up to 59% in patients who need more than existing therapies can offer.
FDA just greenlit Lipfendra, the first oral inhibitor of PCSK9, for treating high cholesterol. For those already on meds but still struggling with high LDL levels, this could be a game-changer. In trials, it slashed LDL-C by an average of 56-59% at Week 24 compared to placebo. If you're managing heart disease risk factors or dealing with hypercholesterolemia in your family history, keep an eye on how this plays out.
Key Points
Lipfendra reduces LDL-C by up to 59% in hypercholesterolemia trials compared to placebo.
The drug received Priority Review and was evaluated under the CNPV pilot program.
Merck Sharp & Dohme LLC is behind this new treatment option for cardiovascular risk management.
Clinical studies involved over 3,207 adults with hypercholesterolemia across two trials.
Discontinuation rates due to adverse reactions were similar between Lipfendra and placebo.
Why It Matters
If you're managing heart disease risk factors or dealing with hypercholesterolemia in your family history, this new treatment could be a game-changer. It offers significant LDL-C reduction for those who need more than current treatments can provide.
Frequently Asked Questions
Why does this matter?
If you're managing heart disease risk factors or dealing with hypercholesterolemia in your family history, this new treatment could be a game-changer. It offers significant LDL-C reduction for those who need more than current treatments can provide.
What happened?
The FDA has approved Lipfendra as an oral treatment for hypercholesterolemia. It reduces LDL-C by up to 59% in patients who need more than existing therapies can offer.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 2,116 builders reading daily.